To investigate the effect of oxygen-driven salbutamol combined with methylprednisolone on bronchial asthma from the perspective of serum molecular markers
Abstract
Objective: This study explores the application of oxygen-driven salbutamol (SA) combined with methylprednisolone (MP) in bronchial asthma (BA) from the perspective of objective clinical markers, including serum inflammatory response, oxidative stress response, immunoglobulin, and pulmonary ventilation function.
Methods: A retrospective analysis was performed on 207 pediatric BA patients admitted to our hospital between January 2022 and January 2025. Of them, 114 children received MP combined with SA nebulization (control group), and 93 children received MP combined with oxygen-driven SA (observation group). The pulmonary ventilation function, inflammatory mediators (HIF-1α, IL-4, IL-6, IL-8 and TNF-α), stress response indicators (SOD, NO, ET-1 and MDA) and immunoglobulin (IgE, IgA, IgM and IgG) were detected and compared before and after treatment.
Results: Post-treatment, the observation group demonstrated superior pulmonary ventilation function and significantly lower levels of inflammatory mediators (HIF-1α, IL-4, IL-6, IL-8, and TNF-α) compared to the control group (P<0.05). Regarding stress response, the SOD level in the observation group was higher after treatment, while the levels of NO, ET-1, and MDA were lower (P<0.05). In addition, IgE was lower and IgA was higher in the observation group after treatment (P<0.05).
Conclusion: The combination of oxygen-driven SA and MP is more effective in mitigating inflammatory, stress responses and optimizing immune function in pediatric BA patients.
Copyright (c) 2025 Lu Qi, Xiao Zhang, Yuanyuan Ju, Xin Yang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.